I believe it was wise for IPIX to PR a statement
I believe it was wise for IPIX to PR a statement regarding the DoD conference cancelation. The fact that the conference was cancelled due to an explosion of the Delta variant is just another proof point for the dire need for an effective CV19 therapeutic. Leo took the opportunity to remind investors that Brilacidin continues to show consistently positive in vitro results against a wide variety of viruses. Delta virus testing is in the queue and IMO will show the same result that Brilacidin penetrates the viral wall and destroys the virus. There will most likely be some real world proof points as well with some of the Russian patients treated in the human trial that likely had the Delta variant.
If you google some of the tested H-CoV strains mentioned in today’s PR (OC43, 229E, NL63), they are species of coronavirus responsible for bronchiolitis, croup, upper and lower respiratory tract infections including pneumonia, and are among the known viruses that cause the common cold. What do you think the overall market is for treating these conditions? Do you think there might be some interest to quickly fund and develop other delivery methods such as an inhaler to address these common ailments and diseases?
IMO the DoD is completely aware of Brilacidin as a Bio Defense asset. They are anxiously awaiting B-CV19 human trial results for final confirmation like all of us investors are. What is clear from today’s PR is that if trial results are positive, there will be enormous demand to fund, procure, partner and accelerate Brilacidin to market.
I expect that IPIX will soon PR that the human trial database has been locked. Within a month or so we will get top line results. My bet is that results will be somewhere in the very good to excellent range. There are many proof points including previous Brilacidin human trials, exhaustive RBL testing specific to CV19, extraordinary Selectivity Index, unique virocidal MOA (penetrates viral wall and kills the virus) and a continual safety profile including the DMC green light to increase frequency dosing form 3 to 5 days.
I understand that some investors are impatient. I initiated my position in CTIX 10 years ago. Investors have experienced blatant criminal attacks on IPIX for over 6 years. Our time is coming very soon. IMO we are part owners of a drug that will save millions of people worldwide and have significant economic impact. We will have confirmation of this very soon and I believe that is when the fun just begins.
13
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Stock Tango Entangled in Legal Webs Ah, Hyliion Holdings Corp. (NYSE American: HYLN) finds itself in the legal crosshairs this time around. On October 20, 2026, DJS Law Group sounded the alarm, reminding investors that there’s a class action lawsuit hanging over Hyliion's head like a gray cloud over a picnic. Allegations of securities law violations are the game of...
Continue Reading
Picture a small business breaking into the spotlight, grabbing the industry’s attention two years in a row: That’s the story of Arbor Scientia Group (ASG), bagging its second consecutive BASA Award. Celebrated within the Education and Training category, this global medical education and communications agency—not just a regular name in the field—has made measurable...
Continue Reading
PetroCal's Double Play in the Real Estate Game When you've been in this game as long as I have, you learn to keep an eye on players who can juggle multiple roles. And that's exactly what PetroCal Associates has pulled off with the Tommy's Express Car Wash project in Orlando. This isn't just another carwash setup, folks. We're talking about integrating into Unicorp...
Continue Reading
Investors Rattled by Chemours' Stark Drop One moment, you're cruising along with the market, and the next, news hits like a brick. That’s what investors in The Chemours Company (NYSE: CC) faced when shares nosedived 18.63% after some unsettling revelations. Let's peel back the layers and see what's got everyone in a tizzy. What's Behind the Lawsuit? Securities lawsuits...
Continue Reading
Igniting Innovation: 2150's New iLAB Network Here's the skinny on what's cookin' at the 2150 Center for Innovation, Commercialization & Growth. They've bagged another cohort for their iLAB network, and they’re laying the groundwork for the next wave of tech solutions that could shake things up across industries. Fresh Collaborations and Technological Foci Essentially,...
Continue Reading
Strategic Moves in a Challenging Market When it rains, it pours. Ashford Hospitality Trust (NYSE: AHT), the real estate investment trust that's got its fingers in the hotel industry pie, is shaking things up with some bold maneuvers. The company just dropped a bombshell: it's waiving a $17 million advisory fee, buying back shares, and terminating its at-the-market (ATM)...
Continue Reading
Change Is Coming to the Las Vegas Strip Las Vegas is about to shake things up in a way not seen for six long decades. Yep, they're breaking ground on a brand new intersection on the Strip! You heard me right—Russell Road and Las Vegas Boulevard are getting some fresh asphalt, thanks to the backing of State Senator Fabian Doñate and Assemblymember Cecelia González....
Continue Reading
AMTD IDEA's Expansive Global Footprint While the rest of the market whirls, AMTD IDEA Group (NYSE: AMTD) is steadying itself with a comprehensive expansion that, quite frankly, demands a second look. Between weaving global media threads and dipping their toes into every alluring venture space, they've formed a tapestry not many could replicate. With facilities stretching...
Continue Reading
Shadeform's Spot Aims To Cut GPU Waste Imagine letting money burn while your GPUs sit in idle mode. That's the reality for many in the cloud computing sector, and Shadeform looks ready to tackle this inefficiency head-on. The launch of Spot, by the GPU Cloud Marketplace Shadeform, offers a novel way to make sure every floating gigaflop translates into some form of...
Continue Reading
Is ODP Getting a Raw Deal? Grab a cup of joe, because this is one of those sticky situations where the stakes are high, and the details are grimmer than last week's sales report. On August 19, 2026, Monteverde & Associates PC filed a lawsuit targeting the acquisition of The ODP Corporation by Atlas Holdings LLC, claiming the buyout price wasn't just low—it was roaringly...
Continue Reading
Top 5 Most Recently Viewed Articles
GraniteShares YieldBOOST ETFs Reveal Weekly Distribution Updates New York - GraniteShares has announced the latest weekly distributions for its popular GraniteShares YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, TQQY, and YSPY. These distributions are crucial for investors looking for steady income through ETF investments. Details of the Latest Distributions The following...
Continue Reading
Samsung Introduces Groundbreaking Galaxy S25 Series Samsung Electronics has recently launched its Galaxy S25 Ultra, Galaxy S25+, and Galaxy S25, revolutionizing the way users interact with smartphones. With the integration of multimodal AI agents, this new series highlights a significant advancement in mobile technology. The power behind these devices comes from a...
Continue Reading
Exploring the Impact of AI on Data Center Services The global data center colocation and managed hosting services market is on a remarkable trajectory, set to grow by an impressive USD 236.9 billion over the next few years. With a compound annual growth rate (CAGR) of 16.82%, this expansion is attributed to the surging demand for data center colocation facilities. The...
Continue Reading
AAON Expands Board Size and Appoints New Director AAON, Inc. (NASDAQ: AAON), a leader in high-performance and energy-efficient HVAC solutions, has announced a significant enhancement to its Board of Directors. The company has increased the board size from eight to nine members and appointed Dr. Matt J. Tobolski as the new director. This change reflects AAON's commitment...
Continue Reading
Moody’s Corporation (NYSE:MCO) is gearing up to drop its Q4 earnings report on February 18, and you know the desks are buzzing about it. Analysts are calling for a hefty jump in earnings per share (EPS), expecting $3.44 compared to last year's $2.62—a spicy leap if they can deliver. Yet, here’s where it gets tricky; while the revenue consensus sits at $1.87 billion,...
Continue Reading